HomeCompareFCBBF vs ABBV

FCBBF vs ABBV: Dividend Comparison 2026

FCBBF yields 4.55% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FCBBF wins by $3622.87M in total portfolio value
10 years
FCBBF
FCBBF
● Live price
4.55%
Share price
$20.45
Annual div
$0.93
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3622.97M
Annual income
$3,476,132,733.83
Full FCBBF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — FCBBF vs ABBV

📍 FCBBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFCBBFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FCBBF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FCBBF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FCBBF
Annual income on $10K today (after 15% tax)
$386.55/yr
After 10yr DRIP, annual income (after tax)
$2,954,712,823.76/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, FCBBF beats the other by $2,954,690,956.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FCBBF + ABBV for your $10,000?

FCBBF: 50%ABBV: 50%
100% ABBV50/50100% FCBBF
Portfolio after 10yr
$1811.54M
Annual income
$1,738,079,229.77/yr
Blended yield
95.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FCBBF
Analyst Ratings
1
Buy
1
Sell
Consensus: Buy
Price Target
$16.30
-20.3% upside vs current
Range: $16.30 — $16.30
Altman Z
0.4
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FCBBF buys
0
ABBV buys
0
No recent congressional trades found for FCBBF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFCBBFABBV
Forward yield4.55%3.12%
Annual dividend / share$0.93$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$3622.97M$104.7K
Annual income after 10y$3,476,132,733.83$25,725.73
Total dividends collected$3612.59M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$16.30$256.15

Year-by-year: FCBBF vs ABBV ($10,000, DRIP)

YearFCBBF PortfolioFCBBF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,610$909.54$11,559$438.51+$51.00FCBBF
2$14,396$1,973.70$13,494$640.86+$902.00FCBBF
3$19,978$4,574.58$15,951$945.97+$4.0KFCBBF
4$33,243$11,866.28$19,152$1,413.89+$14.1KFCBBF
5$72,477$36,906.59$23,443$2,146.38+$49.0KFCBBF
6$227,950$150,400.11$29,391$3,321.96+$198.6KFCBBF
7$1,128,078$884,171.56$37,948$5,265.87+$1.09MFCBBF
8$9,385,707$8,178,662.98$50,795$8,596.74+$9.33MFCBBF
9$137,233,695$127,190,989.30$71,034$14,549.41+$137.16MFCBBF
10$3,622,972,788$3,476,132,733.83$104,715$25,725.73+$3622.87MFCBBF

FCBBF vs ABBV: Complete Analysis 2026

FCBBFStock

FinecoBank Banca Fineco S.p.A. provides banking and investment products and services. The company operates through Banking, Brokerage, and Investing segments. The company offers banking services, including current account and deposit services, payment services, mortgages, and personal loans, as well as debit, credit, and prepaid cards; and brokerage services comprising order execution services on behalf of customers with direct access to global equity markets, as well as to trade on currencies, indices, shares, bonds, commodities, futures, options, bonds, ETFs, and certificates. The company also provides asset management services, such as placement and distribution services of various products, including mutual funds and SICAV sub-funds, and insurance and pension products, as well as investment advisory services. It serves primarily through a network of personal financial advisors, and online and mobile channels. As of December 31, 2021, the company operated 424 financial shops. The company was founded in 1999 and is based in Reggio Emilia, Italy.

Full FCBBF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FCBBF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FCBBF vs SCHDFCBBF vs JEPIFCBBF vs OFCBBF vs KOFCBBF vs MAINFCBBF vs JNJFCBBF vs MRKFCBBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.